The Filings Report

Bristol-Myers Squibb

BMYNYSECIK 14272Healthcare / Drug Manufacturersfiscal year ends December74 quarters since 2008

Revenue, Q3 FY2026
$13.1B
+6.9% on Q3 FY2025
Net income
$2.2B
−1.8% on Q3 FY2025
Free cash flow
$3.8B
−36.0% on Q3 FY2025
Diluted EPS
$1.05
−2.8% on Q3 FY2025
Revenue, TTM
$50.0B
trailing four quarters
Net margin, TTM
18.5%
net income $9.2B
Free cash flow, TTM
$9.3B
$10.7B less $1.4B capex
Cash and equivalents
$9.6B
long-term debt $41.8B, Sep 30, 2026
Shares, 12-month change
+0.4%
2.04B shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
$5.1B
4.0% of market value
Market value
$127.7B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Bristol-Myers Squibb reported revenue of $13.1B, +6.9% on Q3 FY2025, and net income of $2.2B (−1.8%). Free cash flow, operating cash flow less capital expenditures, was $3.8B ($4.2B less $344M). Diluted earnings per share were $1.05.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 29, 2026.

Revenue and net incomeRevenueNet income
−$20B−$10B$0$10B$20BQ4'22, Revenue: $11.4BQ4'22, Net income: $2.0BQ4'22Q1'23, Revenue: $11.3BQ1'23, Net income: $2.3BQ1'23Q2'23, Revenue: $11.2BQ2'23, Net income: $2.1BQ2'23Q3'23, Revenue: $11.0BQ3'23, Net income: $1.9BQ3'23Q4'23, Revenue: $11.5BQ4'23, Net income: $1.8BQ4'23Q1'24, Revenue: $11.9BQ1'24, Net income: −$11.9BQ1'24Q2'24, Revenue: $12.2BQ2'24, Net income: $1.7BQ2'24Q3'24, Revenue: $11.9BQ3'24, Net income: $1.2BQ3'24Q4'24, Revenue: $12.3BQ4'24, Net income: $72MQ4'24Q1'25, Revenue: $11.2BQ1'25, Net income: $2.5BQ1'25Q2'25, Revenue: $12.3BQ2'25, Net income: $1.3BQ2'25Q3'25, Revenue: $12.2BQ3'25, Net income: $2.2BQ3'25Q4'25, Revenue: $12.5BQ4'25, Net income: $1.1BQ4'25Q1'26, Revenue: $11.5BQ1'26, Net income: $2.7BQ1'26Q2'26, Revenue: $13.0BQ2'26, Net income: $3.3BQ2'26Q3'26, Revenue: $13.1BQ3'26, Net income: $2.2BQ3'26−$20B−$10B$0$10B$20BQ4'22, Revenue: $11.4BQ4'22, Net income: $2.0BQ1'23, Revenue: $11.3BQ1'23, Net income: $2.3BQ1'23Q2'23, Revenue: $11.2BQ2'23, Net income: $2.1BQ3'23, Revenue: $11.0BQ3'23, Net income: $1.9BQ3'23Q4'23, Revenue: $11.5BQ4'23, Net income: $1.8BQ1'24, Revenue: $11.9BQ1'24, Net income: −$11.9BQ1'24Q2'24, Revenue: $12.2BQ2'24, Net income: $1.7BQ3'24, Revenue: $11.9BQ3'24, Net income: $1.2BQ3'24Q4'24, Revenue: $12.3BQ4'24, Net income: $72MQ1'25, Revenue: $11.2BQ1'25, Net income: $2.5BQ1'25Q2'25, Revenue: $12.3BQ2'25, Net income: $1.3BQ3'25, Revenue: $12.2BQ3'25, Net income: $2.2BQ3'25Q4'25, Revenue: $12.5BQ4'25, Net income: $1.1BQ1'26, Revenue: $11.5BQ1'26, Net income: $2.7BQ1'26Q2'26, Revenue: $13.0BQ2'26, Net income: $3.3BQ3'26, Revenue: $13.1BQ3'26, Net income: $2.2BQ3'26

Net income losses drawn in red.

Free cash flow
$0$2B$4B$6BQ4'22, Free cash flow: $3.0BQ4'22Q1'23, Free cash flow: $2.7BQ1'23Q2'23, Free cash flow: $1.6BQ2'23Q3'23, Free cash flow: $4.4BQ3'23Q4'23, Free cash flow: $3.9BQ4'23Q1'24, Free cash flow: $2.5BQ1'24Q2'24, Free cash flow: $2.1BQ2'24Q3'24, Free cash flow: $5.3BQ3'24Q4'24, Free cash flow: $4.1BQ4'24Q1'25, Free cash flow: $1.7BQ1'25Q2'25, Free cash flow: $3.6BQ2'25Q3'25, Free cash flow: $6.0BQ3'25Q4'25, Free cash flow: $1.6BQ4'25Q1'26, Free cash flow: $757MQ1'26Q2'26, Free cash flow: $3.1BQ2'26Q3'26, Free cash flow: $3.8BQ3'26$0$2B$4B$6BQ4'22, Free cash flow: $3.0BQ1'23, Free cash flow: $2.7BQ1'23Q2'23, Free cash flow: $1.6BQ3'23, Free cash flow: $4.4BQ3'23Q4'23, Free cash flow: $3.9BQ1'24, Free cash flow: $2.5BQ1'24Q2'24, Free cash flow: $2.1BQ3'24, Free cash flow: $5.3BQ3'24Q4'24, Free cash flow: $4.1BQ1'25, Free cash flow: $1.7BQ1'25Q2'25, Free cash flow: $3.6BQ3'25, Free cash flow: $6.0BQ3'25Q4'25, Free cash flow: $1.6BQ1'26, Free cash flow: $757MQ1'26Q2'26, Free cash flow: $3.1BQ3'26, Free cash flow: $3.8BQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$20B$40B$60BQ4'22, Cash and equivalents: $9.1BQ4'22, Long-term debt: $35.1BQ4'22Q1'23, Cash and equivalents: $9.0BQ1'23, Long-term debt: $35.1BQ1'23Q2'23, Cash and equivalents: $8.4BQ2'23, Long-term debt: $34.7BQ2'23Q3'23, Cash and equivalents: $7.5BQ3'23, Long-term debt: $32.1BQ3'23Q4'23, Cash and equivalents: $11.5BQ4'23, Long-term debt: $36.7BQ4'23Q1'24, Cash and equivalents: $9.3BQ1'24, Long-term debt: $49.5BQ1'24Q2'24, Cash and equivalents: $6.3BQ2'24, Long-term debt: $48.9BQ2'24Q3'24, Cash and equivalents: $7.9BQ3'24, Long-term debt: $48.7BQ3'24Q4'24, Cash and equivalents: $10.3BQ4'24, Long-term debt: $47.6BQ4'24Q1'25, Cash and equivalents: $10.9BQ1'25, Long-term debt: $46.2BQ1'25Q2'25, Cash and equivalents: $12.6BQ2'25, Long-term debt: $44.5BQ2'25Q3'25, Cash and equivalents: $15.7BQ3'25, Long-term debt: $44.5BQ3'25Q4'25, Cash and equivalents: $10.2BQ4'25, Long-term debt: $42.9BQ4'25Q1'26, Cash and equivalents: $9.6BQ1'26, Long-term debt: $42.2BQ1'26Q2'26, Cash and equivalents: $8.7BQ2'26, Long-term debt: $42.1BQ2'26Q3'26, Cash and equivalents: $9.6BQ3'26, Long-term debt: $41.8BQ3'26$0$20B$40B$60BQ4'22, Cash and equivalents: $9.1BQ4'22, Long-term debt: $35.1BQ1'23, Cash and equivalents: $9.0BQ1'23, Long-term debt: $35.1BQ1'23Q2'23, Cash and equivalents: $8.4BQ2'23, Long-term debt: $34.7BQ3'23, Cash and equivalents: $7.5BQ3'23, Long-term debt: $32.1BQ3'23Q4'23, Cash and equivalents: $11.5BQ4'23, Long-term debt: $36.7BQ1'24, Cash and equivalents: $9.3BQ1'24, Long-term debt: $49.5BQ1'24Q2'24, Cash and equivalents: $6.3BQ2'24, Long-term debt: $48.9BQ3'24, Cash and equivalents: $7.9BQ3'24, Long-term debt: $48.7BQ3'24Q4'24, Cash and equivalents: $10.3BQ4'24, Long-term debt: $47.6BQ1'25, Cash and equivalents: $10.9BQ1'25, Long-term debt: $46.2BQ1'25Q2'25, Cash and equivalents: $12.6BQ2'25, Long-term debt: $44.5BQ3'25, Cash and equivalents: $15.7BQ3'25, Long-term debt: $44.5BQ3'25Q4'25, Cash and equivalents: $10.2BQ4'25, Long-term debt: $42.9BQ1'26, Cash and equivalents: $9.6BQ1'26, Long-term debt: $42.2BQ1'26Q2'26, Cash and equivalents: $8.7BQ2'26, Long-term debt: $42.1BQ3'26, Cash and equivalents: $9.6BQ3'26, Long-term debt: $41.8BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Bristol-Myers Squibb income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed Apr 24, 2025Q4 FY2024ended Dec 31, 2024filed Feb 12, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue13,06912,97311,48912,50212,22212,26911,20112,342+6.9%
Cost of revenue4,1463,7263,4214,0973,4353,3723,0334,812+20.7%
Gross profit—————————
Research and development2,3652,9592,6492,5862,5282,5802,2573,191−6.4%
Selling, general and administrative1,6991,8261,6172,1811,7891,7131,5842,136−5.0%
Operating income—————————
Other income (expense)(307)61(32)51108(494)(339)(305)−384.3%
Pretax income2,5364,0863,2401,4703,1141,7732,971175−18.6%
Income tax37477056138491946050999−59.3%
Net income2,1623,3172,6771,0872,2011,3102,45672−1.8%
Diluted EPS ($)1.051.621.31—1.080.641.20—−2.8%
Diluted shares (millions)2,0532,0482,047—2,0392,0382,040——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Bristol-Myers Squibb balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed Apr 24, 2025Q4 FY2024ended Dec 31, 2024filed Feb 12, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents9,5748,7229,57410,20915,72612,59910,87510,346−39.1%
Short-term investments3,0072,3459124647761,004907513+287.5%
Total current assets29,76728,57927,20829,39035,63033,22230,78329,780−16.5%
Total assets88,77287,63486,47690,03896,88994,67692,42792,603−8.4%
Total current liabilities18,75318,65919,15823,41728,13627,52824,07023,774−33.3%
Long-term debt41,84942,09342,15242,85044,46944,47046,15747,603−5.9%
Total liabilities65,36865,31566,37471,53378,28977,18774,97976,215−16.5%
Stockholders’ equity23,40422,31920,06818,47318,55217,43517,38916,335+26.2%
Shares outstanding (millions)2,0442,0432,0422,0362,0362,0352,0352,029—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Bristol-Myers Squibb cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed Apr 24, 2025Q4 FY2024ended Dec 31, 2024filed Feb 12, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow4,1813,3931,1041,9746,3113,9171,9544,439−33.8%
Capital expenditures344305347370320361260378+7.5%
Free cash flow (CFO − capex)3,8373,0887571,6045,9913,5561,6944,061−36.0%
Depreciation and amortization6265945949771,0111,0111,0121,880−38.1%
Share repurchases———————0—
Dividends paid1,2871,2871,2831,2621,2631,2621,2581,218+1.9%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 11, 2026.

Income statement

Bristol-Myers Squibb income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 11, 2026FY2024ended Dec 31, 2024filed Feb 12, 2025FY2023ended Dec 31, 2023filed Feb 13, 2024FY2022ended Dec 31, 2022filed Feb 14, 2023FY2021ended Dec 31, 2021filed Feb 9, 2022FY2020ended Dec 31, 2020filed Feb 10, 2021FY2019ended Dec 31, 2019filed Feb 24, 2020FY2018ended Dec 31, 2018filed Feb 25, 2019FY2017ended Dec 31, 2017filed Feb 13, 2018FY2016ended Dec 31, 2016filed Feb 21, 2017FY2015ended Dec 31, 2015filed Feb 12, 2016FY2014ended Dec 31, 2014filed Feb 13, 2015FY2013ended Dec 31, 2013filed Feb 14, 2014FY2012ended Dec 31, 2012filed Feb 15, 2013FY2011ended Dec 31, 2011filed Feb 17, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Feb 19, 2010FY2008ended Dec 31, 2008filed Jul 23, 2009FY2007ended Dec 31, 2007filed Jul 23, 2009
Revenue48,19448,30045,00646,15946,38542,51826,14522,56120,77619,42716,56015,87916,38517,62121,24419,48418,80817,71515,617
Cost of revenue13,93613,96810,69310,1379,94011,7738,0786,4676,0144,969—————————
Gross profit—————30,74518,06716,09414,68214,48112,65111,94711,76613,01115,64614,20713,668——
Research and development9,95111,1599,2999,50910,19510,0486,1486,3326,4685,0125,9204,5343,7313,9043,8393,5663,6473,5123,160
Selling, general and administrative7,2678,4147,7727,8147,6907,6614,8714,5514,7514,9794,8414,8224,9394,2204,2033,6863,9464,1403,941
Operating income———————————————————
Other income (expense)(674)(893)1,158(576)7202,314(938)8541,6851,448187(210)(205)8033493381(22)(77)
Pretax income9,328(8,379)8,4407,7138,098(6,871)4,9755,9685,1315,9152,0772,3812,8912,3406,9816,0715,6024,7762,523
Income tax2,2725544001,3681,0842,1241,5151,0214,1561,408446352311(161)1,7211,5581,1821,090471
Net income7,054(8,948)8,0256,3276,994(9,015)3,4394,9201,0074,4571,5652,0042,5631,9603,7093,10210,6125,2472,165
Diluted EPS ($)3.46(4.41)3.862.953.12(3.99)2.013.010.612.650.931.201.541.162.161.795.342.621.09
Diluted shares (millions)2,0392,0272,0782,1462,2452,2581,7121,6371,6521,6801,6791,6701,6621,6881,7171,7271,978——

Balance sheet

Bristol-Myers Squibb balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 11, 2026FY2024ended Dec 31, 2024filed Feb 12, 2025FY2023ended Dec 31, 2023filed Feb 13, 2024FY2022ended Dec 31, 2022filed Feb 14, 2023FY2021ended Dec 31, 2021filed Feb 9, 2022FY2020ended Dec 31, 2020filed Feb 10, 2021FY2019ended Dec 31, 2019filed Feb 24, 2020FY2018ended Dec 31, 2018filed Feb 25, 2019FY2017ended Dec 31, 2017filed Feb 13, 2018FY2016ended Dec 31, 2016filed Feb 21, 2017FY2015ended Dec 31, 2015filed Feb 12, 2016FY2014ended Dec 31, 2014filed Feb 13, 2015FY2013ended Dec 31, 2013filed Feb 14, 2014FY2012ended Dec 31, 2012filed Feb 15, 2013FY2011ended Dec 31, 2011filed Feb 17, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Feb 19, 2010FY2008ended Dec 31, 2008filed Jul 23, 2009FY2007ended Dec 31, 2007filed Jul 23, 2009
Cash and equivalents10,20910,34611,4649,12313,97914,54612,3466,9115,4214,2372,3855,5713,5861,6565,7765,0337,6837,9761,801
Short-term investments4645138161302,9871,2853,0471,8481,3912,1131,8851,8649391,1732,9572,268831289—
Total current assets29,39029,78031,77027,27333,26230,19229,35417,71614,85413,70410,41514,60818,9169,52115,31813,27313,95814,697—
Total assets90,03892,60395,15996,820109,314118,481129,94434,98633,55133,70731,74833,74938,59235,89732,97031,07631,00829,486—
Total current liabilities23,41723,77422,26221,89021,86819,08018,30410,6549,5638,8418,0178,46112,4408,2797,7806,7396,3136,710—
Long-term debt42,85047,60336,65335,05639,60548,33643,3875,6466,9755,7166,5507,2427,9816,5685,3765,3286,1306,585—
Total liabilities71,53376,21565,67465,70273,30880,59978,24620,85921,70417,36017,32418,76623,35622,25917,10315,43816,22317,278—
Stockholders’ equity18,47316,33529,43031,06135,94637,82251,59814,03111,74116,17714,26614,85215,15413,62315,95615,71314,84312,241—
Shares outstanding (millions)2,0362,0292,0222,0992,1802,2402,2581,6331,6331,6731,6691,6621,6501,6431,6881,7021,714——

Cash flow statement

Bristol-Myers Squibb cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 11, 2026FY2024ended Dec 31, 2024filed Feb 12, 2025FY2023ended Dec 31, 2023filed Feb 13, 2024FY2022ended Dec 31, 2022filed Feb 14, 2023FY2021ended Dec 31, 2021filed Feb 9, 2022FY2020ended Dec 31, 2020filed Feb 10, 2021FY2019ended Dec 31, 2019filed Feb 24, 2020FY2018ended Dec 31, 2018filed Feb 25, 2019FY2017ended Dec 31, 2017filed Feb 13, 2018FY2016ended Dec 31, 2016filed Feb 21, 2017FY2015ended Dec 31, 2015filed Feb 12, 2016FY2014ended Dec 31, 2014filed Feb 13, 2015FY2013ended Dec 31, 2013filed Feb 14, 2014FY2012ended Dec 31, 2012filed Feb 15, 2013FY2011ended Dec 31, 2011filed Feb 17, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Feb 19, 2010FY2008ended Dec 31, 2008filed Jul 23, 2009FY2007ended Dec 31, 2007filed Jul 23, 2009
Operating cash flow14,15615,19013,86013,06616,20714,0528,2107,0665,2753,0582,1053,1483,5456,9414,8404,4914,0653,7073,153
Capital expenditures1,3111,2481,2091,1189737538369511,0551,215820526537548367424730941843
Free cash flow (CFO − capex)12,84513,94212,65111,94815,23413,2997,3746,1154,2201,8431,2852,6223,0086,3934,4734,0673,3352,7662,310
Depreciation and amortization4,0119,6009,76010,27610,68610,3801,746637789382376467763681628607———
Share repurchases005,1558,0016,2871,5467,3003202,469231——4332,4031,221576———
Dividends paid5,0454,8634,7444,6344,3964,0752,6792,6132,5772,5472,4772,3982,3092,2862,2542,2022,4832,4612,213

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$437K
2 sales by 2 insiders; officers and directors $437K
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$2M
4 sales by 3 insiders; officers and directors $2M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 2, 2026Gallman CariEVP, General Counseloption exercise4,559$0.00—18,208Oct 5, 2026
Oct 2, 2026Gallman CariEVP, General Counseltax withholding2,332$61.15$143K15,876Oct 5, 2026
Sep 9, 2026Massacesi CristianEVP,Chief Med Offr,Head of Devopen-market sale6,249$64.57$403K18,748Sep 10, 2026
Sep 1, 2026Short Bartie WendyEVP, Corporate Affairsoption exercise1,236$66.92$83K13,317Sep 3, 2026
Sep 1, 2026Short Bartie WendyEVP, Corporate Affairstax withholding633$66.92$42K12,684Sep 3, 2026
Aug 25, 2026Holzer Phil MSVP and Controlleropen-market sale500$67.50$34K16,862Aug 26, 2026
Aug 1, 2026Massacesi CristianEVP,Chief Med Offr,Head of Devoption exercise51,172$0.00—51,172Aug 4, 2026
Aug 1, 2026Massacesi CristianEVP,Chief Med Offr,Head of Devtax withholding26,175$65.31$2M24,997Aug 4, 2026
Aug 1, 2026Gallman CariEVP, General Counseloption exercise1,061$0.00—14,192Aug 4, 2026
Aug 1, 2026Gallman CariEVP, General Counseltax withholding543$65.31$35K13,649Aug 4, 2026
Jun 15, 2026Haller Julia ADirectoroption exercise20,460$53.76$1M34,079Jun 16, 2026
Jun 3, 2026Short Bartie WendyEVP, Corporate Affairsoption exercise8,040$0.00—15,957Jun 5, 2026
Jun 3, 2026Short Bartie WendyEVP, Corporate Affairstax withholding3,876$54.72$212K12,081Jun 5, 2026
May 1, 2026Lenkowsky AdamEVP, Chief Commercial Officeroption exercise1,373$0.00—20,508May 5, 2026
May 1, 2026Lenkowsky AdamEVP, Chief Commercial Officerother203$0.00—20,305May 5, 2026
May 1, 2026Lenkowsky AdamEVP, Chief Commercial Officertax withholding599$58.22$35K19,706May 5, 2026
Apr 1, 2026Shanahan KarinEVP, Chief Supply Chain & Opsoption exercise3,307$0.00—27,580Apr 2, 2026
Apr 1, 2026Shanahan KarinEVP, Chief Supply Chain & Opstax withholding1,692$61.73$104K25,888Apr 2, 2026
Apr 1, 2026Elkins David VEVP, Chief Financial Officeropen-market sale25,519$61.60$2M163,729Apr 2, 2026
Apr 1, 2026Elkins David VEVP, Chief Financial Officeropen-market sale4,481$62.05$278K159,248Apr 2, 2026
Mar 10, 2026Short Bartie WendyEVP, Corporate Affairsoption exercise749$0.00—6,780Mar 12, 2026
Mar 10, 2026Short Bartie WendyEVP, Corporate Affairsother81$0.00—6,699Mar 12, 2026
Mar 10, 2026Short Bartie WendyEVP, Corporate Affairstax withholding242$60.13$15K6,457Mar 12, 2026
Mar 10, 2026Short Bartie WendyEVP, Corporate Affairsoption exercise4,495$0.00—10,952Mar 12, 2026
Mar 10, 2026Short Bartie WendyEVP, Corporate Affairsoption exercise639$0.00—6,308Mar 12, 2026

Full insider history for Bristol-Myers Squibb, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
BRISTOL-MYERS SQUIBB COMPANY, CIK 14272 on EDGAR
Extract generated
October 30, 2026
Withheld
1 line-years whose four quarters do not sum to the filed year: buybacks FY2022
Repaired
2 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2012, other income FY2021
XBRL concepts behind each line

Income statement

Revenue: Revenues, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated October 30, 2026.

JSON file
/data/financials/BMY.json